Phase I dose escalation trial of biweekly pemetrexed in combination with docetaxel in advanced solid tumors

13019 Background: Pemetrexed (PEM) and docetaxel (DOC) are cytotoxic agents with a broad range of activity in solid tumors and relatively non-overlapping toxicities. We are conducting a single site...